Literature DB >> 23413937

EUCAST technical note on voriconazole and Aspergillus spp.

W W Hope1, M Cuenca-Estrella, C Lass-Flörl, M C Arendrup.   

Abstract

The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for voriconazole against Aspergillus spp. This Technical Note is based on the EUCAST rationale document for voriconazole (available on the EUCAST website: http://www.eucast.org). Voriconazole breakpoints are based on epidemiological cut-off values, pharmacokinetic/pharmacodynamic data and clinical experience. Breakpoints will be reviewed regularly or when new data emerge.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23413937     DOI： 10.1111/1469-0691.12148

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  27 in total

1.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  High prevalence of extended-spectrum-cephalosporin-resistant enterobacteriaceae in poultry meat in Switzerland: emergence of CMY-2- and VEB-6-possessing Proteus mirabilis.

Authors:  Salome N Seiffert; Regula Tinguely; Agnese Lupo; Catherine Neuwirth; Vincent Perreten; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

3.  Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.

Authors:  Carlo Tascini; Francesco Sbrana; Sarah Flammini; Enrico Tagliaferri; Fabio Arena; Alessandro Leonildi; Ilaria Ciullo; Francesco Amadori; Antonello Di Paolo; Andrea Ripoli; Russell Lewis; Gian Maria Rossolini; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

4.  Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.

Authors:  Shivaprakash M Rudramurthy; Seyedmojtaba Seyedmousavi; Manpreet Dhaliwal; Arunaloke Chakrabarti; Jacques F Meis; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Aspergillus Section Fumigati Clinical Isolates.

Authors:  S Dellière; L Verdurme; J Bigot; E Dannaoui; Y Senghor; F Botterel; A Fekkar; M E Bougnoux; C Hennequin; J Guitard
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 6.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

7.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

8.  In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

Authors:  Prajna Lalitha; Catherine Q Sun; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Vicky Cevallos; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman
Journal:  Am J Ophthalmol       Date:  2013-10-22       Impact factor: 5.258

9.  Carbapenemase-producing enterobacteriaceae in Spain in 2012.

Authors:  Jesús Oteo; David Saez; Verónica Bautista; Sara Fernández-Romero; Juan Manuel Hernández-Molina; María Pérez-Vázquez; Belén Aracil; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

10.  OXA-48 carbapenemase-producing Salmonella enterica serovar Kentucky isolate of sequence type 198 in a patient transferred from Libya to Switzerland.

Authors:  Salome N Seiffert; Vincent Perreten; Sönke Johannes; Sara Droz; Thomas Bodmer; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.